PDCD1 and melanoma: In the non-immunogenic B16F10 melanoma model, systemic PD-1 antibody monotherapy failed to suppress tumor progression, while RT + CpG + αOX40 triple vaccine reactivated the therapeutic potential of checkpoint blockade, and synergize with αPD-1 to further augment tumor suppression and prolong survival.